Outcomes after photodynamic therapy of basalcell carcinoma on the eyelid skin with intravenous administration of photosensitizer chloride E6
https://doi.org/10.37895/2071-8004-2024-28-1-25-32
Abstract
Purpose. To evaluate immediate and long-term outcomes after photodynamic therapy (PDT) of basal cell carcinoma (BCC) on the eyelid with intravenous administration of photosensitizer (PS) chlorine E6.
Materials and methods. PDT was performed in 261 patients with a verified diagnosis of BCC of the eyelid cT1-3N0MO, stage I–II, aged 38 to 87 (average 68.7 ± 15.6). PS chlorin E6 (Photolon, Photoditazin, Radachlorin) was used intravenously at dosage 1.0–1.5mg/kg; 1–2 courses. Light dosage ranged from 100 to 300 J/cm2, depending on the neoplasm clinical form and the data of fluorescence diagnostics.
Results. Complete regression after the first PDT course of eyelid BCC cT1-3N0M0 with intravenous administration of PS chlorin E6 was obtained in 90.4 % of cases; after 2 courses - in 96.2 % of cases. During the follow-up period from 5 to 15 years, relapses were diagnosed in 7.6 % of cases. The number of relapses depended on the process stage. In neoplasms corresponding to the symbol cT1a, the number of relapses was 1.4 %, cT1 b – 5.0 %, cT1 c– 8.3 %, cT2 a – 2.5 %, cT2 b – 5.0 %, cT2 c – 9 %, cT3 a – 5.8 %, cT3 b – 43.8 %, cT3 c – 46.7 %. Good and excellent cosmetic results were seen too.
Conclusion. PDT of eyelid BCC of stage I–II with intravenous administration of PS chlorine E6 is an effective and low-risk method for anatomical and functional disorders. It can be an alternativetechnique to surgical treatment. The discussed way of treatment should be personalized and provided in specialized medical settings.
About the Authors
E. V. Yaroslavtseva-Isaeva
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Center of Radiology
Russian Federation
Russian Federation
Yaroslavtseva-Isaeva E.V. – Cand. Sci. (Med.), leading researcher of the department of photodynamic diagnostics and therapy
Obninsk
V. N. Kapinus
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Center of Radiology
Russian Federation
Russian Federation
Kapinus Viktoriya Nikolaevna – Cand. Sci. (Med.), senior researcher of the department of FDD and therapy
Obninsk
O. E. Popovkina
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Center of Radiology
Russian Federation
Russian Federation
Popovkina Olga Efi movna – Cand. Sci. (Med.), head of the department of FDD and therapy
Obninsk
I. S. Spichenkova
A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Center of Radiology
Russian Federation
Russian Federation
Spichenkova Irina Sergeevna – Cand. Sci. (Med.), researcher of the department of FDD and therapy
Obninsk
References
1. Zlokachestvennye novoobrazovaniya v 2021 g. (zabolevaemost’ i smertnost’). Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoi. Moscow: MNIOI im. P.A.Gertsena – branch of NMITs radiologii, 2022. [In Russ.].
2. Brovkina A.F., Lerner M.Yu. Eyelid skin cancer: еpidemiology, prognosis. Opukholi golovi i shei. 2017; 7 (1): 81–85.
3. Bagheri А., Tavakoli M., Kanaani A. et al. Eyelid masses: A 10-year survey from a tertiary eye hospital in Tehran. Middle East Afr J Ophthalmol. 2013; 20: 187–92. PMID: 24014978. DOI: 10.4103/0974-9233.114788
4. NCCN Guidelines Versijns 2. 2022. Bazal Cell Skin Cancer.
5. Grusha Ya.O., Ismailova D.S., Rizopulu E.F. Surgical treatment for malignant epithelial eyelid neoplasms. Opukholi golovi i shei. 2012; (2): 24–28.
6. Bochkareva A.N., Kolenko O.V., Yegorov V.V., Smolyakova G.P., Banshchikov P.A., Pilipenko A.D., Belous A.V. Improving the effectiveness of the treatment of malignant neoplasms of the eyelids. Public Health of the Far East, 2020; 2: 36–39. [In Russ.]. DOI: 10.33454/1728-1261-2020-2-36-39
7. Aaron M. Drucker, Gaelen P. Adam et al. Treatments of Primary Basal Cell Carcinoma of the Skin: A Systematic Review and Network Meta-analysis; 2018: Oct 2; 169 (7): 456–466.
8. Knani O., Romdhane N. Ben Rayana. Clinical study and risk factors for recurrence of basal cell carcinoma of the eyelid: results of a Tunisian series and review of the literature J. Fr. Ophtalmol. 2014 Feb; 37 (2): 107–114. DOI: 10.1016/j.jfo.2013.05.028.
9. Fatigato G., Capitani S., Milani D., Grassilli S., Alameen A.A., Candiani M., Riberti C., Galasso M., Previati M., Eur J. Risk factors associated with relapse of eyelid basalcellcarcinoma: results from a retrospective study of 142 patients. Dermatol. 2017; 27 (4): 363–368. DOI: 10.1684/ejd.2017.3026
10. Paavilainen V., Tuominen J., Aho V.V., Saari K.M. Long-term results after treatment of basal cell carcinoma of the eyelid in South-Western Finland. Eur J Ophthalmol. 2007; 17 (4): 494–500. DOI: 10.1177/112067210701700403
11. Panova I.E., Vasil’ev S.A., Semenova L.E., Pilat A.V., Pavlenko E.S., Dudnil S.N., Vazhenina D.A. Recurrent basal cell carcinoma of lids skin (peculiarities of clinical course, treatment). Rossiisky mediztinsky zhurnal. 2006; 11: 36–43. [In Russ.].
12. Volgin V.N., Stranadko E.F., Trishkina O.V., Kabanova M.A., Kagoyants R.V. Comparative characteristics of therapies for cutaneous basal-cell carcinoma. Rossiisky zhurnal kozhnikh I venericheskikh boleznei. 2013; (5): 4–10. [In Russ.].
13. Kapinus V.N., Kaplan M.A., Yaroslavtseva-Isayeva E.V., Spichenkova I.S., Ivanov S.A. Chlorin E6-photodynamic therapy basal cell carcinoma. Rossiisky zhurnal kozhnikh I venericheskikh boleznei. 2021; 4 (8): 33–43. [In Russ.].
14. Filonenko E.V., Serova L.G. Photodynamic therapy in clinical practice. Biomedical Photonics. 2016; 5 (2): 26–37. [In Russ.].
15. Stranadko E.Ph., Riabov M.V. Photodynamic therapy of skin cancer of critical anatomical locations in the geriatric practice. Lazernaya medicina. 2021; 25 (3S): 36–37. [In Russ.].
16. Purtshvanidze V.A. Photodynamic therapy of skin cancer inner corner of eye and lower eyelids. Vestnik meditzinskikh tekhnologii. 2016; 3: 114–121. [In Russ.].
17. Arits A.H., Mosterd K., Essers B.A., Spoorenberg E., Sommer A., De Rooij M.J., van Pelt H.P., Quaedvlieg P.J., Krekels G.A., van Neer P.A., Rijzewijk J.J., van Geest A.J., Steijlen P.M., Nelemans P.J., Kelleners-Smeets N.W. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013 Jun; 14 (7): 647–54. DOI: 10.1016/S1470-2045(13)70143-8
18. Van Delft L.C. J , Nelemans P. J, Kessels J. P. H. M., Kreukels H., Roozeboom M. H , Michette de Rooij J. M. , Mosterd K., Ellen de Haas R. M. , Kelleners-Smeets N. W J. Long-Term Efficacy of Photodynamic Therapy with Fractionated 5-Aminolevulinic Acid 20 % versus Conventional Two-Stage Topical Methyl Aminolevulinate for Superficial Basal-Cell Carcinoma. Dermatology. 2022; 238 (6): 1044–1049. DOI: 10.1159/000524745
19. Thomson J., Hogan S. Interventions for basal cell carcinoma of the skin. Codraine Database Syst Rev. 2020; 11 (11): CD003412. DOI: 10.1002/14651858.CD003412.pub3
20. Savoia P., Deboli T., Previgliano A., Dummer Р. et al Usefulness of Photodynamic Therapy as a Possible Therapeutic Alternative in the Treatment of Basal Cell Carcinoma. Int J Mol Sci. 2015; 16 (10): 23300–23317.
Review
For citations:
Yaroslavtseva-Isaeva E.V., Kapinus V.N., Popovkina O.E., Spichenkova I.S. Outcomes after photodynamic therapy of basalcell carcinoma on the eyelid skin with intravenous administration of photosensitizer chloride E6. Laser Medicine. 2024;28(1):27-34. (In Russ.) https://doi.org/10.37895/2071-8004-2024-28-1-25-32
Views:
117
Email this article 